Calidi Biotherapeutics Statistics
Total Valuation
CLDI has a market cap or net worth of $10.68 million. The enterprise value is $3.62 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDI has 7.32 million shares outstanding. The number of shares has increased by 571.35% in one year.
| Current Share Class | 7.17M |
| Shares Outstanding | 7.32M |
| Shares Change (YoY) | +571.35% |
| Shares Change (QoQ) | +70.56% |
| Owned by Insiders (%) | 4.45% |
| Owned by Institutions (%) | 3.89% |
| Float | 6.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.49 |
| P/TBV Ratio | 1.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.12, with a Debt / Equity ratio of 0.46.
| Current Ratio | 2.12 |
| Quick Ratio | 2.00 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.24 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -119.65% |
| Return on Invested Capital (ROIC) | -254.37% |
| Return on Capital Employed (ROCE) | -224.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$915,000 |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLDI has paid $20,000 in taxes.
| Income Tax | 20,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.73% in the last 52 weeks. The beta is 1.08, so CLDI's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | -93.73% |
| 50-Day Moving Average | 1.52 |
| 200-Day Moving Average | 4.52 |
| Relative Strength Index (RSI) | 47.18 |
| Average Volume (20 Days) | 171,071 |
Short Selling Information
The latest short interest is 170,321, so 2.33% of the outstanding shares have been sold short.
| Short Interest | 170,321 |
| Short Previous Month | 120,339 |
| Short % of Shares Out | 2.33% |
| Short % of Float | 2.79% |
| Short Ratio (days to cover) | 0.78 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.80M |
| Pretax Income | -20.13M |
| Net Income | -25.62M |
| EBITDA | -19.31M |
| EBIT | -19.80M |
| Earnings Per Share (EPS) | -$9.02 |
Full Income StatementBalance Sheet
The company has $10.38 million in cash and $3.31 million in debt, giving a net cash position of $7.07 million or $0.97 per share.
| Cash & Cash Equivalents | 10.38M |
| Total Debt | 3.31M |
| Net Cash | 7.07M |
| Net Cash Per Share | $0.97 |
| Equity (Book Value) | 7.20M |
| Book Value Per Share | 0.98 |
| Working Capital | 5.84M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.67 million and capital expenditures -$96,000, giving a free cash flow of -$21.77 million.
| Operating Cash Flow | -21.67M |
| Capital Expenditures | -96,000 |
| Free Cash Flow | -21.77M |
| FCF Per Share | -$2.97 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |